Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06326931 · ClinicalTrials.gov registry record · Phase 4
Thermal Pulsation Versus Warm Compress Treatment for Meibomian Gland Dysfunction
A Phase 4 study of Meibomian Gland Dysfunction, sponsored by Jacksoneye.
- Completed
- Registry status
- Phase 4
- Development phase
- 68
- Enrollment target
- 1
- Study location
NCT06326931: Completed Phase 4 study of Meibomian Gland Dysfunction, sponsored by Jacksoneye.
NCT06326931 is a Phase 4 study of Meibomian Gland Dysfunction that has completed, run by Jacksoneye. The registered enrollment target is 68 participants, below the 94-participant average among 8 other Meibomian Gland Dysfunction trials with a reported enrollment target (28% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06326931, a Phase 4 study of Meibomian Gland Dysfunction, has completed, sponsored by Jacksoneye.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 68 participants
- Enrollment target
- 1
- Study location
Study Summary
This study aimed to assess the treatment outcome differences between a single, in-office bilateral treatment with the thermal pulsation system and twice-daily, 10-minute applications of the warm compress mask at home for 8 weeks.
Primary Outcome
Change in MGS score for the worse eye
Conditions Studied
Interventions
- DEVICE thermal pulsation
- OTHER warm compress
Study Locations (1)
Illinois
- Jacksoneye - Lake Villa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2022-06-24 |
| Est. Completion | 2023-06-22 |
| Phase | Phase 4 |
What the finished NCT06326931 record still lists
NCT06326931 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 68 participants, a relatively small participant target, below the 94-participant average among 8 other Meibomian Gland Dysfunction trials with a reported enrollment target (28% lower).
The record links to 1 condition, with Meibomian Gland Dysfunction appearing as the primary indexed condition, and to 2 interventions - of which thermal pulsation is the first listed.
NCT06326931 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT06326931 about?
NCT06326931 is a clinical study titled "Thermal Pulsation Versus Warm Compress Treatment for Meibomian Gland Dysfunction". This study aimed to assess the treatment outcome differences between a single, in-office bilateral treatment with the thermal pulsation system and twice-daily, 10-minute applications of the warm compress mask at home for 8 weeks.
What is the current status of trial NCT06326931?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 68 participants. The study started on 2022-06-24. Estimated completion is 2023-06-22.
What conditions does trial NCT06326931 study?
This clinical trial studies the following conditions: Meibomian Gland Dysfunction.
What interventions are being tested in trial NCT06326931?
The interventions under investigation include: thermal pulsation (DEVICE), warm compress (OTHER).
Who is sponsoring clinical trial NCT06326931?
This trial is sponsored by Jacksoneye, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06326931 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Meibomian Gland Dysfunction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06326931's enrollment target sits among peer trials
68 5th of 8 higher than 4 of 8 other Meibomian Gland Dysfunction trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Meibomian Gland Dysfunction trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effect of an Exploratory Vehicle on Meibomian Gland Dysfunction in Patients With Demodex
ACTIVE NOT RECRUITING · Phase 2
-
Meibomian Gland Dysfunction Management
ACTIVE NOT RECRUITING · NA
-
Clinical Study Evaluating Nordlys™ SWT IPL for Dry Eye Disease (DED) Due to MGD
ACTIVE NOT RECRUITING · NA
-
Comparison Between iLux™ and LipiFlow® in the Treatment of Meibomian Gland Dysfunction
COMPLETED · NA
-
The Efficacy of an Ocular Emulsion in Meibomian Gland Dysfunction
COMPLETED · NA
-
Comparison Between iLux and LipiFlow in the Treatment of Meibomian Gland Dysfunction (MGD): A 12-month, Multicenter Study
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02044497 · 68 participants · Phase 4
Population Pharmacokinetics and Pharmacogenomics of Oral Oxycodone in Pediatric Surgical Patients
- NCT03779854 · 68 participants · Phase 2
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
- NCT03821246 · 68 participants · Phase 2
Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy
- NCT04115514 · 68 participants · Phase 2
Treatment of ARDS With Instilled T3
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI